Adrenomed AG

@adrenomed

Clinical stage biopharmaceutical company specialized in preserving vascular integrity in life-threatening conditions such as sepsis and septic shock

Vrijeme pridruživanja: studeni 2018.

Tweetovi

Blokirali ste korisnika/cu @adrenomed

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @adrenomed

  1. proslijedio/la je Tweet
    4. velj

    Today is - many people still aren't aware of the relationship between and - sepsis rates are 4 times higher in cancer patients, and cancer patients have a 55% higher chance of dying from sepsis than non-cancer patients. |

    , , i još njih 7
    Poništi
  2. 17. sij

    is killing more people than cancer. Learn more about Adrenomed’s lead product candidate: a first-in-class antibody counteracting vascular leakage and shock to rescue in sepsis.

    Poništi
  3. 10. sij

    wishes you a great start of #2020. We will kick off the new year by travelling to for networking and 1o1s at . Our CEO, CBO and our CSO will represent the Company. We look forward to a successful experience in

    Poništi
  4. proslijedio/la je Tweet
    22. pro 2019.
    Poništi
  5. 16. pro 2019.

    Today, leading experts will meet in Berlin during the symposium “Mortality in Sepsis” co-hosted by . The event will cover many topics, including how applying novel therapies and tools can positively impact the journey of a patient w/ or .

    Poništi
  6. 15. stu 2019.

    develops a new strategy against : tackle the disease heterogeneity through intervening downstream in the pathological process by targeting . Read more about the science behind it and the company’s mission in

    Poništi
  7. 12. stu 2019.

    „Umsteuern bei “ in der neuen Ausgabe: Von gesundheitspolitischen Maßnahmen über Diagnostika bis hin zu innovativen personalisierten Therapieansätzen wie dem Antikörper

    Poništi
  8. 12. stu 2019.

    Today, our CBO, Dr. Hein, will give a presentation at , 11:15 AM, Level 1/Hall B1/Room 6 🎤👩‍🏫. Join and discover how tackles by restoring with its first-in-class

    Poništi
  9. 11. stu 2019.

    opens its doors to countless networking opportunities for global life science partners. Are you ready? Dr. Schneider-Mergener, CEO, Dr. Hein, CBO, are representing at the conference. Join the company presentation tomorrow 👨‍🔬🎤👩‍🏫

    Poništi
  10. 4. stu 2019.

    In less than a week, will be heading off to to attend , 11-13.11.! Join the company presentation to learn about our program to rescue in ! See you there!

    Poništi
  11. proslijedio/la je Tweet
    1. stu 2019.

    Sepsis is a really tough field, but is trying a new approach; it's not about the cause, they say, but about the progression to septic shock. Via

    Poništi
  12. 28. lis 2019.

    We are getting ready for , EU's largest life science partnering conference, 11-13.11! Use to set up a meeting with us and discover the potential of our lead product, the first-in-class 👨‍💻👩🏻‍💼👨🏻‍💼➡️🤝

    Poništi
  13. proslijedio/la je Tweet
    22. lis 2019.

    We are less than three away until ✈️📍 Who are you most excited to meet! 🙋🙋‍♂️

    Poništi
  14. proslijedio/la je Tweet
    22. lis 2019.

    BIO-Europe® 2019: companies follow the footsteps of ’s ancient merchants as they gather to celebrate innovation and partnership

    Poništi
  15. proslijedio/la je Tweet
    26. ruj 2019.

    did you know: The many waterways of Hamburg are spanned by around 2,500 bridges—more than the bridges in Venice, Amsterdam & London combined? Come see beautiful Hamburg for yourself. Register now ->

    Poništi
  16. proslijedio/la je Tweet
    7. lis 2019.

    Partnering is now open for 2019! Register now and be ready to request meetings with 4,500+ potential partners 🤝>>

    Poništi
  17. 2. lis 2019.

    It was a splendid experience . We thank Prof. Peter Pickkers for his talk “ in , effect of the non-inhibitory antibody ” and all participants and organizers for this amazing event.

    Poništi
  18. 1. lis 2019.

    Today, Dr. Peter Pickkers will give a talk “ in , effect of the non-inhibitory antibody . This drug candidate developed by has a novel MoA to restore

    Poništi
  19. 26. ruj 2019.

    announces the successful completion of enrollment in the 300-patient PoC Phase II trial, AdrenOSS-2. “By restoring , we aim to provide physicians with a new therapy for patients,” said Dr. Andreas Bergmann, CSO

    Poništi
  20. 25. ruj 2019.

    Dr. Frauke Hein, CBO of , will give a “Spotlight Talk on Sepsis” today at the in . Discover the latest knowledge on and ’s role in tackling this awful disease by restoring

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·